The Evolution of Therapies in Non-Small Cell Lung Cancer.

Boolell, Vishal; Alamgeer, Muhammad; Watkins, David N; Ganju, Vinod

Boolell, Vishal; Alamgeer, Muhammad; Watkins, David N; Ganju, Vinod.

Afiliación

Boolell V; Department of Medical Oncology, Monash Medical Centre, 823-865 Centre Road, East Bentleigh VIC 3165, Australia. vishal.boolell@monashhealth.org.au.
Alamgeer M; Hudson Institute of Medical Research, Monash University, 27-31 Wright Street, Clayton VIC 3168, Australia. vishal.boolell@monashhealth.org.au.
Watkins DN; Department of Medical Oncology, Monash Medical Centre, 823-865 Centre Road, East Bentleigh VIC 3165, Australia. n.watkins@garvan.org.au.
Ganju V; Hudson Institute of Medical Research, Monash University, 27-31 Wright Street, Clayton VIC 3168, Australia. n.watkins@garvan.org.au.

Cancers (Basel) ; 7(3): 1815-46, 2015 Sep 09.

Article en En | MEDLINE | ID: mdl-26371045

Palabras clave

PD-1 inhibitors; anaplastic lymphoma kinase (ALK); cytotoxic T lymphocyte antigen-4 (CTLA-4); epidermal growth factor receptor (EGFR); immuno-oncology; non-small cell lung cancer (NSCLC); programmed death-1 receptor (PD-1); tyrosine kinase inhibitors

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2015 Tipo del documento: Article País de afiliación: Australia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google